Acrivon Therapeutics, Inc. Common Stock Cash Flow
Concept
Operating Cash Flow
Net Income
Depreciation & Amortization
Stock based compensation
Other non cash items
Change in working capital
Investing Cash Flow
Capital Expenditures
Financing Cash Flow
Dividends Paid
Payout Ratio
Share Issuance / Repurchase
Debt Issued / Paid
Other Investing Activities
End Cash Position
Changes in Cash
Beginning Cash Position
Free Cash Flow
2023
2022
2021
2020
-43M
-60M
1M
12M
1M
8M
-65M
1M
-2M
0M
-0 %
0M
0M
-1M
36M
6M
30M
-44M
-30M
-31M
0M
2M
0M
-2M
-140M
2M
102M
0M
-0 %
102M
0M
-3M
30M
-70M
100M
-32M
-14M
-16M
0M
0M
1M
0M
0M
0M
112M
0M
-0 %
0M
0M
0M
100M
98M
2M
-14M
-3M
-5M
0M
0M
2M
0M
0M
0M
3M
0M
-0 %
0M
0M
0M
2M
0M
2M
-3M
Concept
Operating Cash Flow
Net Income
Depreciation & Amortization
Stock based compensation
Other non cash items
Change in working capital
Investing Cash Flow
Capital Expenditures
Financing Cash Flow
Dividends Paid
Payout Ratio
Share Issuance / Repurchase
Debt Issued / Paid
Other Investing Activities
End Cash Position
Changes in Cash
Beginning Cash Position
Free Cash Flow
4Q2023
3Q2023
2Q2023
1Q2023
4Q2022
3Q2022
2Q2022
1Q2022
4Q2021
3Q2021
2Q2021
1Q2021
-12M
-19M
0M
0M
3M
4M
0M
1M
-2M
0M
-0 %
0M
0M
-1M
36M
6M
30M
-14M
-10M
-14M
0M
3M
0M
2M
2M
0M
0M
0M
-0 %
0M
0M
2M
30M
-8M
38M
-10M
-9M
-14M
0M
3M
0M
3M
19M
0M
0M
0M
-0 %
0M
0M
19M
38M
11M
28M
-9M
-11M
-13M
0M
3M
-1M
0M
9M
0M
0M
0M
-0 %
0M
0M
9M
28M
-2M
30M
-11M
-9M
-9M
0M
2M
0M
-2M
-95M
0M
102M
0M
-0 %
0M
0M
2M
30M
-3M
32M
-10M
-7M
-9M
0M
0M
0M
2M
-45M
0M
0M
0M
-0 %
0M
0M
0M
32M
-52M
84M
-7M
-6M
-6M
0M
0M
0M
0M
-1M
1M
0M
0M
-0 %
0M
0M
-1M
84M
-7M
91M
-7M
-8M
-7M
0M
0M
0M
-1M
0M
0M
0M
0M
-0 %
0M
0M
0M
91M
-9M
100M
-9M
-4M
-4M
0M
0M
0M
0M
0M
0M
100M
0M
-0 %
0M
0M
0M
100M
96M
4M
-4M
-2M
-2M
0M
0M
0M
0M
0M
0M
0M
0M
-0 %
0M
0M
0M
4M
-2M
6M
-2M
-4M
-5M
0M
0M
0M
0M
0M
0M
6M
0M
0 %
0M
0M
0M
6M
2M
0M
0M
-4M
-5M
0M
0M
0M
0M
0M
0M
6M
0M
0 %
0M
0M
0M
0M
2M
0M
0M